In a separate press release, Biohaven stated that its oral anti-CGRP drug, Nurtec ODT, was recommended by the Committee for Medicinal Products for Human Use for approval in Europe as an acute and preventive treatment for migraine. The company expects approval from the European Commission in the first half of 2022. During the fourth quarter, the drug received approval in Israel as acute and preventive treatment and in Kuwait as an acute treatment for migraine.